The role of hydrogen therapy in Alzheimer's disease management: Insights into mechanisms, administration routes, and future challenges.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 25 08 2023
revised: 25 10 2023
accepted: 26 10 2023
medline: 15 11 2023
pubmed: 2 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

Alzheimer's disease (AD) is a progressive neurodegenerative disorder predominantly affecting the elderly. While conventional pharmacological therapies remain the primary treatment for AD, their efficacy is limited effectiveness and often associated with significant side effects. This underscores the urgent need to explore alternative, non-pharmacological interventions. Oxidative stress has been identified as a central player in AD pathology, influencing various aspects including amyloid-beta metabolism, tau phosphorylation, autophagy, neuroinflammation, mitochondrial dysfunction, and synaptic dysfunction. Among the emerging non-drug approaches, hydrogen therapy has garnered attention for its potential in mitigating these pathological conditions. This review provides a comprehensively overview of the therapeutic potential of hydrogen in AD. We delve into its mechanisms of action, administration routes, and discuss the current challenges and future prospects, with the aim of providing valuable insights to facilitate the clinical application of hydrogen-based therapies in AD management.

Identifiants

pubmed: 37913734
pii: S0753-3322(23)01605-0
doi: 10.1016/j.biopha.2023.115807
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115807

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jiaxuan He (J)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.

Fan Liu (F)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.

Ting Xu (T)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.

Jiahui Ma (J)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.

Haiyang Yu (H)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.

Jing Zhao (J)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.

Yanyan Xie (Y)

The Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Li Luo (L)

Dongguan Hospital, Southern Medical University, Dongguan 523059, China.

Qinsi Yang (Q)

Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.

Ting Lou (T)

Yiwu Center for Disease Control and Prevention, Yiwu 322000, China. Electronic address: louting22@163.com.

Luqing He (L)

Department of Science and Education, the Third People's Hospital Health Care Group of Cixi, Ningbo 315300, China. Electronic address: helq619@163.com.

Da Sun (D)

Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China. Electronic address: sunday@wzu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH